Heavily Shorted KemPharm Reports Higher Revenue, Elimination of Debt and FDA Approval For AZSTARYS™ NDA

Pharmaceutical company KemPharm shares have risen after $KMPH received approval for the AZSTARYS NDA an alternative for Adderall and other ADHD treatments. In there fourth quarter earnings they announced a restructured its balance sheet, extinguished its debt and re-listed on The Nasdaq Capital Market. The stock is also heavily shorted.